{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:22:32Z","timestamp":1773940952580,"version":"3.50.1"},"reference-count":135,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014653","name":"Manchester Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.lpm.2025.104319","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:45:54Z","timestamp":1761788754000},"page":"104319","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological management of COPD"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-5364","authenticated-orcid":false,"given":"Augusta","family":"Beech","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2025.104319_bib0001","year":"2025","journal-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2025 report"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0002","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00164-2019","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019","volume":"53","author":"Singh","year":"2019","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0003","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1183\/09031936.00162414","article-title":"Eosinophilic inflammation in COPD: prevalence and clinical characteristics","volume":"44","author":"Singh","year":"2014","journal-title":"Eur Respir J"},{"issue":"18","key":"10.1016\/j.lpm.2025.104319_bib0004","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2025.104319_bib0006","article-title":"Effect of triple therapy on cardiovascular and severe cardiopulmonary events in COPD: a post-hoc analysis of a randomized, double-blind, phase 3 clinical trial (ETHOS)","author":"Singh","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0007","first-page":"33","article-title":"Mortality risk and serious cardiopulmonary events in moderate-to-severe COPD: post hoc analysis of the IMPACT trial","volume":"10","author":"Wells","year":"2023","journal-title":"Chronic Obstr Pulm Dis"},{"issue":"24","key":"10.1016\/j.lpm.2025.104319_bib0008","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1056\/NEJMoa2401304","article-title":"Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation","volume":"390","author":"Bhatt","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0009","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2303951","article-title":"Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts","volume":"389","author":"Bhatt","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0010","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1124\/pr.119.018150","article-title":"Pharmacology and therapeutics of bronchodilators revisited","volume":"72","author":"Matera","year":"2020","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0011","article-title":"Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease","author":"Sestini","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.lpm.2025.104319_bib0012","series-title":"Global strategy for prevention, diagnosis and management of COPD: 2024 report","year":"2024"},{"issue":"160","key":"10.1016\/j.lpm.2025.104319_bib0013","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0023-2021","article-title":"Future concepts in bronchodilation for COPD: dual- versus monotherapy","volume":"30","author":"Singh","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0014","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1586\/17512433.2015.1058154","article-title":"Long-acting muscarinic antagonists","volume":"8","author":"Melani","year":"2015","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0015","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.tips.2014.11.005","article-title":"Acetylcholine beyond bronchoconstriction: roles in inflammation and remodeling","volume":"36","author":"Kistemaker","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0016","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1185\/03007995.2016.1145108","article-title":"Safety of long acting muscarinic antagonists: are all these drugs always and equally safe?","volume":"32","author":"Melani","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.lpm.2025.104319_bib0017","doi-asserted-by":"crossref","first-page":"697","DOI":"10.2147\/COPD.S62502","article-title":"Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate 48-week studies","volume":"9","author":"Koch","year":"2014","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0018","article-title":"Long-acting beta2-agonists for chronic obstructive pulmonary disease","author":"Kew","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/thoraxjnl-2014-206732","article-title":"Efficacy and safety of long-acting beta-agonist\/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis","volume":"71","author":"Oba","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.lpm.2025.104319_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pupt.2017.12.005","article-title":"Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease","volume":"49","author":"Donohue","year":"2018","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0021","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12931-020-01589-5","article-title":"The TRIFLOW study: a randomised, cross-over study evaluating the effects of extrafine beclometasone\/formoterol\/glycopyrronium on gas trapping in COPD","volume":"21","author":"Dean","year":"2020","journal-title":"Respir Res"},{"issue":"164","key":"10.1016\/j.lpm.2025.104319_bib0022","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0196-2021","article-title":"The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review","volume":"31","author":"Calzetta","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0023","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S2213-2600(18)30102-4","article-title":"Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial","volume":"6","author":"Calverley","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S2213-2600(13)70052-3","article-title":"Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2025.104319_bib0025","doi-asserted-by":"crossref","DOI":"10.1177\/14799731231202257","article-title":"How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?","volume":"20","author":"Kerwin","year":"2023","journal-title":"Chron Respir Dis"},{"issue":"12","key":"10.1016\/j.lpm.2025.104319_bib0026","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1007\/s12325-016-0430-6","article-title":"Assessing short-term deterioration in maintenance-na\u00efve patients with COPD receiving umeclidinium\/vilanterol and tiotropium: a pooled analysis of three randomized trials","volume":"33","author":"Maleki-Yazdi","year":"2017","journal-title":"Adv Ther"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0027","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","article-title":"Efficacy of tiotropium + olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis","volume":"32","author":"Ferguson","year":"2015","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0028","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1007\/s12325-020-01411-0","article-title":"Efficacy of tiotropium\/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are na\u00efve to LAMA, LABA and ICS: pooled analysis of four clinical trials","volume":"37","author":"Buhl","year":"2020","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0029","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/resp.13651","article-title":"Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-na\u00efve COPD patients: a pooled analysis","volume":"25","author":"Muro","year":"2020","journal-title":"Respirology"},{"key":"10.1016\/j.lpm.2025.104319_bib0030","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.2147\/COPD.S217710","article-title":"An evaluation of single and dual long-acting bronchodilator therapy as effective interventions in maintenance therapy-na\u00efve patients with COPD","volume":"14","author":"Singh","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0031","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12931-020-1332-3","article-title":"Glycopyrrolate\/formoterol fumarate metered dose inhaler for maintenance-naive patients with chronic obstructive pulmonary disease: a post-hoc analysis of the randomized PINNACLE trials","volume":"21","author":"Zheng","year":"2020","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.lpm.2025.104319_bib0032","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1164\/rccm.201505-1048OC","article-title":"FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol\/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease","volume":"192","author":"Mahler","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0033","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1186\/s12931-019-1193-9","article-title":"Efficacy of umeclidinium\/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial","volume":"20","author":"Maltais","year":"2019","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0034","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.rmed.2012.12.016","article-title":"Fluticasone furoate\/vilanterol (100\/25; 200\/25 \u03bcg) improves lung function in COPD: a randomised trial","volume":"107","author":"Martinez","year":"2013","journal-title":"Respir Med"},{"issue":"170","key":"10.1016\/j.lpm.2025.104319_bib0035","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0084-2023","article-title":"How inhaled corticosteroids target inflammation in COPD","volume":"32","author":"Lea","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"9","key":"10.1016\/j.lpm.2025.104319_bib0036","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1164\/rccm.201908-1550OC","article-title":"Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A network analysis","volume":"201","author":"Martinez-Garcia","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0037","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00515-2020","article-title":"Osteoporosis and fracture risk associated with inhaled corticosteroid use among Swedish COPD patients: the ARCTIC study","volume":"57","author":"Janson","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2025.104319_bib0038","doi-asserted-by":"crossref","DOI":"10.1038\/npjpcrm.2016.30","article-title":"Extrafine beclometasone diproprionate\/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease","volume":"26","author":"Singh","year":"2016","journal-title":"NPJ Prim Care Respir Med"},{"issue":"10048","key":"10.1016\/j.lpm.2025.104319_bib0039","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0040","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S2213-2600(18)30327-8","volume":"6","author":"Ferguson","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0041","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1164\/rccm.201703-0449OC","article-title":"FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease","volume":"196","author":"Lipson","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0042","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S2213-2600(18)30006-7","article-title":"Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials","volume":"6","author":"Bafadhel","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0043","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1164\/rccm.201502-0235LE","article-title":"Blood eosinophils: a biomarker of response to extrafine beclomethasone\/formoterol in chronic obstructive pulmonary disease","volume":"192","author":"Siddiqui","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0044","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S2213-2600(15)00106-X","article-title":"Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials","volume":"3","author":"Pascoe","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.lpm.2025.104319_bib0045","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S2213-2600(19)30190-0","article-title":"Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial","volume":"7","author":"Pascoe","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0046","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01393-2017","article-title":"Cigarette smoking and response to inhaled corticosteroids in COPD","volume":"51","author":"Bhatt","year":"2018","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0047","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010099","article-title":"Identification of responders to inhaled corticosteroids in a chronic obstructive pulmonary disease population using cluster analysis","volume":"6","author":"Hinds","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0048","doi-asserted-by":"crossref","first-page":"00660","DOI":"10.1183\/23120541.00870-2023","article-title":"Current smoking reduces small airway eosinophil counts in COPD","volume":"10","author":"Beech","year":"2024","journal-title":"ERJ Open Res"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0049","first-page":"413","article-title":"Predictors of high sputum eosinophils in chronic obstructive pulmonary disease","volume":"9","author":"Wen","year":"2022","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.lpm.2025.104319_bib0050","first-page":"327","article-title":"Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD","volume":"5","author":"Wen","year":"2010","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0051","doi-asserted-by":"crossref","first-page":"00051","DOI":"10.1183\/23120541.00686-2023","article-title":"Exhaled nitric oxide, eosinophils and current smoking in COPD patients","volume":"9","author":"Higham","year":"2023","journal-title":"ERJ Open Res"},{"issue":"12","key":"10.1016\/j.lpm.2025.104319_bib0052","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2213-2600(17)30432-0","article-title":"Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort","volume":"5","author":"Hastie","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0053","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1164\/ajrccm.158.5.9804028","article-title":"Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis","volume":"158","author":"Pizzichini","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.lpm.2025.104319_bib0054","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1164\/rccm.200905-0685OC","article-title":"Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide","volume":"180","author":"Dummer","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0055","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.115.3.697","article-title":"Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema","volume":"115","author":"Fujimoto","year":"1999","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0056","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000221902","article-title":"Sputum IL-5 concentration is associated with a sputum eosinophilia and attenuated by corticosteroid therapy in COPD","volume":"78","author":"Bafadhel","year":"2009","journal-title":"Respiration"},{"issue":"7","key":"10.1016\/j.lpm.2025.104319_bib0057","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/rccm.200508-1321OC","article-title":"Antiinflammatory effects of salmeterol\/fluticasone propionate in chronic obstructive lung disease","volume":"173","author":"Barnes","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0058","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/thorax.58.4.299","article-title":"Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD","volume":"58","author":"Sugiura","year":"2003","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.lpm.2025.104319_bib0059","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1164\/rccm.2105025","article-title":"The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study","volume":"165","author":"Hattotuwa","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.lpm.2025.104319_bib0060","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/thx.2006.071068","article-title":"Effect of salmeterol\/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial","volume":"62","author":"Bourbeau","year":"2007","journal-title":"Thorax"},{"issue":"8","key":"10.1016\/j.lpm.2025.104319_bib0061","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7326\/0003-4819-151-8-200910200-00004","article-title":"Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial","volume":"151","author":"Lapperre","year":"2009","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.lpm.2025.104319_bib0062","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/thorax.57.8.694","article-title":"Effects of fluticasone propionate in COPD patients with bronchial hyperresponsiveness","volume":"57","author":"Verhoeven","year":"2002","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0063","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1440-1843.2008.01380.x","article-title":"Bronchodilator reversibility, airway eosinophilia and anti-inflammatory effects of inhaled fluticasone in COPD are not related","volume":"13","author":"Reid","year":"2008","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0064","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/all.14661","article-title":"Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease","volume":"76","author":"Higham","year":"2021","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0065","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.lpm.2025.104319_bib0066","first-page":"1195","article-title":"Th2 high and mast cell gene signatures are associated with corticosteroid sensitivity in COPD","volume":"77","author":"Faiz","year":"2022","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0067","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.chest.2024.06.3790","article-title":"Rethinking blood eosinophils for assessing inhaled corticosteroids response in COPD: a post hoc analysis from the FLAME trial","volume":"166","author":"Mathioudakis","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0068","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00427-2018","article-title":"The reproducibility of COPD blood eosinophil counts","volume":"52","author":"Southworth","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0069","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12931-020-1279-4","article-title":"The stability of blood eosinophils in chronic obstructive pulmonary disease","volume":"21","author":"Long","year":"2020","journal-title":"Respir Res"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0070","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.3390\/biomedicines10102611","article-title":"Identification of COPD inflammatory endotypes using repeated sputum eosinophil counts","volume":"10","author":"Beech","year":"2022","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0071","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3390\/biomedicines9101337","article-title":"Airway bacteria quantification using polymerase chain reaction combined with neutrophil and eosinophil counts identifies distinct COPD endotypes","volume":"9","author":"Beech","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0072","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12931-019-1085-z","article-title":"Airway host-microbiome interactions in chronic obstructive pulmonary disease","volume":"20","author":"Wang","year":"2019","journal-title":"Respir Res"},{"issue":"12","key":"10.1016\/j.lpm.2025.104319_bib0073","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.202009-3448OC","article-title":"Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis","volume":"203","author":"Wang","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0074","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00451-2017","article-title":"Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD","volume":"50","author":"Contoli","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0075","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1164\/rccm.202102-0289OC","article-title":"Effects of inhaled corticosteroid\/long-acting beta(2)-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease: a randomized controlled clinical trial (DISARM)","volume":"204","author":"Leitao Filho","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.lpm.2025.104319_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107506","article-title":"Impact of COPD on mortality: an 8-year observational retrospective healthcare claims database cohort study","volume":"222","author":"Vogelmeier","year":"2024","journal-title":"Respir Med"},{"issue":"8","key":"10.1016\/j.lpm.2025.104319_bib0077","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1056\/NEJMoa063070","article-title":"Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease","volume":"356","author":"Calverley","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0078","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1164\/rccm.202006-2618OC","article-title":"Reduced all-cause mortality in the ETHOS trial of budesonide\/glycopyrrolate\/formoterol for chronic obstructive pulmonary disease. A randomized, double-blind, multicenter, parallel-group study","volume":"203","author":"Martinez","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.lpm.2025.104319_bib0079","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1164\/rccm.201911-2207OC","article-title":"Reduction in all-cause mortality with fluticasone furoate\/umeclidinium\/vilanterol in patients with chronic obstructive pulmonary disease","volume":"201","author":"Lipson","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0080","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01230-2018","article-title":"Inhaled corticosteroid containing combinations and mortality in COPD","volume":"52","author":"Vestbo","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0081","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41533-023-00347-6","article-title":"Rational use of inhaled corticosteroids for the treatment of COPD","volume":"33","author":"Quint","year":"2023","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.lpm.2025.104319_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2022.106857","volume":"197","author":"Singh","year":"2022","journal-title":"Respir Med"},{"issue":"10030","key":"10.1016\/j.lpm.2025.104319_bib0083","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(16)30069-1","article-title":"Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial","volume":"387","author":"Vestbo","year":"2016","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0084","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02364-2022","article-title":"Quantifying COPD as a risk factor for cardiac disease in a primary prevention cohort","volume":"62","author":"Maclagan","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0085","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1164\/rccm.201711-2239OC","article-title":"Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial","volume":"198","author":"Kunisaki","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0086","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1183\/09031936.00128806","article-title":"Possible protection by inhaled budesonide against ischaemic cardiac events in mild COPD","volume":"29","author":"L\u00f6fdahl","year":"2007","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0087","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s12325-024-02855-4","article-title":"Implications of cardiopulmonary risk for the management of COPD: a narrative review","volume":"41","author":"Singh","year":"2024","journal-title":"Adv Ther"},{"issue":"9","key":"10.1016\/j.lpm.2025.104319_bib0088","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s11606-018-4518-3","article-title":"Incidence of acute cardiovascular event after acute exacerbation of COPD","volume":"33","author":"Goto","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"16","key":"10.1016\/j.lpm.2025.104319_bib0089","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40265-021-01616-9","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs"},{"issue":"9691","key":"10.1016\/j.lpm.2025.104319_bib0090","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0091","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1164\/rccm.201607-1349OC","article-title":"Effect of roflumilast and inhaled corticosteroid\/long-acting \u03b22-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial","volume":"194","author":"Martinez","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0092","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12931-019-1142-7","article-title":"Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD","volume":"20","author":"Singh","year":"2019","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0093","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1186\/s12931-020-01512-y","article-title":"Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study","volume":"21","author":"Singh","year":"2020","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0094","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12931-020-1329-y","article-title":"Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis","volume":"21","author":"Govoni","year":"2020","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0095","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94888","article-title":"PDE3 in allergic airway inflammation","volume":"3","author":"Beute","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0096","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0097","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1164\/rccm.202307-1164ED","article-title":"A new treatment for chronic obstructive pulmonary disease: ensifentrine moves closer","volume":"208","author":"Singh","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0098","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S2213-2600(14)70019-0","article-title":"Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Uzun","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.lpm.2025.104319_bib0099","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1164\/rccm.200801-145OC","article-title":"Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations","volume":"178","author":"Seemungal","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.lpm.2025.104319_bib0100","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0101","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3390\/diseases11040152","article-title":"The effectiveness and safety of long-term macrolide therapy for COPD in stable status: a systematic review and meta-analysis","volume":"11","author":"Nakamura","year":"2023","journal-title":"Diseases"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0102","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.chest.2021.02.019","article-title":"The association of long-term macrolide therapy and nontuberculous mycobacterial culture positivity in patients with bronchiectasis","volume":"160","author":"Metersky","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0103","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/jleuko\/qiae153","article-title":"The relevance of eosinophils in chronic obstructive pulmonary disease: inflammation, microbiome, and clinical outcomes","volume":"116","author":"Higham","year":"2024","journal-title":"J Leukoc Biol"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0104","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jaci.2017.04.027","article-title":"Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts","volume":"140","author":"Kolsum","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0105","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1016\/S2213-2600(24)00266-2","article-title":"Anti-interleukin-4 receptor therapy for COPD with dupilumab?","volume":"12","author":"Virchow","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0106","article-title":"Type 2 inflammation in COPD: is it just asthma?","volume":"20","author":"Beech","year":"2024","journal-title":"Breathe (Sheff)"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0107","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1186\/s12890-024-03320-2","article-title":"Blood eosinophil count correlates with alveolar damage in emphysema-predominant COPD","volume":"24","author":"Nakamura","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0108","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0109","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00150-2024","article-title":"Type 2 airway inflammation in COPD","volume":"63","author":"Polverino","year":"2024","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lpm.2025.104319_bib0110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.lpm.2025.104319_bib0111","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of COPD exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.lpm.2025.104319_bib0112","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0113","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S2213-2600(19)30338-8","article-title":"Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies","volume":"8","author":"Criner","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0114","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","article-title":"IL-4 and IL-13 signaling in allergic airway disease","volume":"75","author":"Gour","year":"2015","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0115","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.lpm.2025.104319_bib0116","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0117","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.4049\/jimmunol.181.4.2790","article-title":"Expression and cellular provenance of thymic stromal lymphopoietin and chemokines in patients with severe asthma and chronic obstructive pulmonary disease","volume":"181","author":"Ying","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.lpm.2025.104319_bib0118","doi-asserted-by":"crossref","first-page":"L375","DOI":"10.1152\/ajplung.00045.2007","article-title":"Constitutive and inducible thymic stromal lymphopoietin expression in human airway smooth muscle cells: role in chronic obstructive pulmonary disease","volume":"293","author":"Zhang","year":"2007","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"10.1016\/j.lpm.2025.104319_bib0119","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/rccm.202303-0455CI","article-title":"Targeting type 2 inflammation and epithelial alarmins in chronic obstructive pulmonary disease: a biologics outlook","volume":"208","author":"Rabe","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0120","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000329131","article-title":"Viral stimuli trigger exaggerated thymic stromal lymphopoietin expression by chronic obstructive pulmonary disease epithelium: role of endosomal TLR3 and cytosolic RIG-I-like helicases","volume":"4","author":"Calven","year":"2012","journal-title":"J Innate Immun"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0121","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0122","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(24)00324-2","article-title":"Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial","volume":"13","author":"Singh","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.lpm.2025.104319_bib0123","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1164\/rccm.202210-1881OC","article-title":"IL-33 expression is lower in current smokers at both transcriptomic and protein levels","volume":"208","author":"Faiz","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.lpm.2025.104319_bib0124","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/S2213-2600(21)00167-3","article-title":"Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial","volume":"9","author":"Rabe","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0125","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S2213-2600(21)00556-7","article-title":"Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial","volume":"10","author":"Yousuf","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"Suppl 68","key":"10.1016\/j.lpm.2025.104319_bib0126","first-page":"PA4933","article-title":"Late breaking abstract - FRONTIER-4: a phase 2a study to investigate tozorakimab (anti-IL-33 mAb) in COPD","volume":"64","author":"Pandya","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2025.104319_bib0127","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02231-2024","article-title":"A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4","author":"Singh","year":"2025","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/15412555.2017.1335697","article-title":"A randomized, placebo-controlled phase 2 trial of CNTO 6785 in chronic obstructive pulmonary disease","volume":"14","author":"Eich","year":"2017","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.lpm.2025.104319_bib0129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12931-017-0633-7","article-title":"A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease","volume":"18","author":"Calverley","year":"2017","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.lpm.2025.104319_bib0130","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease","volume":"191","author":"Rennard","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0131","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01037-2023","article-title":"The association of blood eosinophil counts and FEV(1) decline: a cohort study","volume":"63","author":"Hong","year":"2024","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2025.104319_bib0132","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00838-2020","article-title":"High eosinophil counts predict decline in FEV(1): results from the CanCOLD study","volume":"57","author":"Tan","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2025.104319_bib0133","series-title":"COPD in the 21st century","article-title":"Eosinophils and COPD","author":"Beech","year":"2024"},{"issue":"3","key":"10.1016\/j.lpm.2025.104319_bib0134","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1164\/rccm.202107-1663SO","article-title":"Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients: time to move forward","volume":"205","author":"Martinez","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.lpm.2025.104319_bib0135","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1164\/rccm.202311-2180PP","article-title":"Call to action: how can we promote the development of new pharmacologic treatments in chronic obstructive pulmonary disease?","volume":"210","author":"Belz","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498225000521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:24:59Z","timestamp":1773879899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498225000521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0755498225000521"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104319","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological management of COPD","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2025.104319","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104319"}}